134 related articles for article (PubMed ID: 19534284)
1. Significantly increased accuracy of urothelial carcinoma detection in destained urine slides with combined analysis of standard cytology and CK-20 immunostaing.
Soyuer I; Tokat F; Tasdemir A
Acta Cytol; 2009; 53(3):357-60. PubMed ID: 19534284
[No Abstract] [Full Text] [Related]
2. Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?
Buchumensky V; Klein A; Zemer R; Kessler OJ; Zimlichman S; Nissenkorn I
J Urol; 1998 Dec; 160(6 Pt 1):1971-4. PubMed ID: 9817302
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic Advances in Urine Cytology.
Xing J; Reynolds JP
Surg Pathol Clin; 2018 Sep; 11(3):601-610. PubMed ID: 30190143
[TBL] [Abstract][Full Text] [Related]
4. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic value of cytohistological urine analysis and cytokeratin 20 in malignant and atypical urothelial cells.
Negri S; Biavati P; Bondi A
Pathologica; 2016 Sep; 108(3):130-135. PubMed ID: 28195264
[TBL] [Abstract][Full Text] [Related]
6. Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panel.
Irwin T; Donlan AW; Owens L; Alvarez R; Vakar-Lopez F; Tretiakova M
Hum Pathol; 2024 Apr; 146():43-48. PubMed ID: 38593961
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin 20 immunocytochemistry on urine sediments: A potential low-cost adjunct to cytology in the diagnosis of low-grade urothelial carcinoma.
Wadhwa N; Diwaker P; Lotha N; Arora VK; Singh N
Cytopathology; 2017 Dec; 28(6):531-535. PubMed ID: 28940433
[TBL] [Abstract][Full Text] [Related]
8. Cytomorphology of urothelial carcinomatous peritoneal effusion.
Xiao GQ
Cytopathology; 2008 Apr; 19(2):131-3. PubMed ID: 18241206
[No Abstract] [Full Text] [Related]
9. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
10. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
11. CD138-positive plasmacytoid urothelial carcinoma of the bladder.
Patriarca C; Di Pasquale M; Giunta P; Bergamaschi F
Int J Surg Pathol; 2008 Apr; 16(2):215-7. PubMed ID: 18417684
[No Abstract] [Full Text] [Related]
12. Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review.
Sanguedolce F; Russo D; Calò B; Cindolo L; Carrieri G; Cormio L
Pathol Res Pract; 2019 Jun; 215(6):152413. PubMed ID: 30987832
[TBL] [Abstract][Full Text] [Related]
13. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.
Babu S; Mockler DC; Roa-Peña L; Szygalowicz A; Kim NW; Jahanfard S; Gholami SS; Moffitt R; Fitzgerald JP; Escobar-Hoyos LF; Shroyer KR
Mod Pathol; 2019 May; 32(5):717-724. PubMed ID: 30443013
[TBL] [Abstract][Full Text] [Related]
14. Detection of urinary bladder cancer with flow cytometry and hexaminolevulinate in urine samples.
Cunderlíková B; Wahlqvist R; Berner A; Vasovic V; Warloe T; Nesland JM; Peng Q
Cytopathology; 2007 Apr; 18(2):87-95. PubMed ID: 17397493
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 Antibody Comparison in Urothelial Carcinoma.
Rijnders M; van der Veldt AAM; Zuiverloon TCM; Grünberg K; Thunnissen E; de Wit R; van Leenders GJLH
Eur Urol; 2019 Mar; 75(3):538-540. PubMed ID: 30497882
[No Abstract] [Full Text] [Related]
16. Sensitivity and specificity of urine cytology in the screening of transitional cell carcinomas.
Keir JA; Womack C
Cytopathology; 2002 Dec; 13(6):381-2. PubMed ID: 12485176
[No Abstract] [Full Text] [Related]
17. The applicability and utility of immunohistochemical biomarkers in bladder pathology.
Akgul M; MacLennan GT; Cheng L
Hum Pathol; 2020 Apr; 98():32-55. PubMed ID: 32035992
[TBL] [Abstract][Full Text] [Related]
18. Nested variant of urothelial carcinoma.
Dhall D; Al-Ahmadie H; Olgac S
Arch Pathol Lab Med; 2007 Nov; 131(11):1725-7. PubMed ID: 17979494
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of double immunocytochemical staining for CK20 and P53 as a potential adjunct to cytology for urothelial cancer diagnosis.
Lenos M; Katafigiotis I; Vrettou K; Papaioannou D; Malta F; Trigka EA; Sousouris S; Constantinides C; Mikou P
Cytopathology; 2017 Apr; 28(2):96-102. PubMed ID: 27859848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
